The HOPE Study (Heart Outcomes Prevention Evaluation)

Abstract

Keywords

HOPE angiotensin converting enzyme inhibitors cardiovascular morbidity mortality cardiovascular risk

Get full access to this article

View all access options for this article.

References

Yusuf S. , Pepine CJ , Garces C. et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340:1173-1178.

The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New Engl J Med 1992; 327: 685-691.

The SOLVD Investigators. Effect of enalapril on survival in patients with reduced ejection fractions and congestive heart failure. New Engl J Med 1991; 325: 293-302.

Pfeffer MA , Braunwald L. , Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med 1992; 327: 669-677.

The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients. New Engl J Med 2000; 342:145-153.

The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high risk patients. New Engl J Med 2000; 342:154-160.

The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and Micro-HOPE substudy. Lancet 2000; 355: 253-259.

Hansson L. , Lindholm LH , Niskanen L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPP) randomised trial. Lancet 1999; 353: 611-616.

Francis GS ACE inhibition in cardiovascular disease. New Engl J Med 2000; 342: 201-202.

10.

Hansson L. , Zanchetti A. , Carruthers SG et al, for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351: 1755-1762.

11.

UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular complications in type-2 diabetes: UKPDS 38. Br Med J 1998;317:703-713.

12.

Hansson L. , Lindholm LH , Ekbom T. et al, for the STOP-Hypertension-2 Study Group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756.

13.

Staessen JA , Fagard B. , Thijs L. et al, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764.